16:00-17:00 GMT | 11:00-12:00 EST | 08:00-09:00 PST
Thursday, June 8, 2017
Current methods to assay miRNA expression rely on Northern blotting, PCR-based methods, miRNA microarrays, Next Generation Sequencing (NGS), or in situ hybridization. Next generation and microarray-based approaches can globally assay miRNA expression and abundance in cells and tissues.
However, these methods are inherently biased. Microarray based methods do not have the power to distinguish between targets that are equally expressed in multiple tissues. NGS based methods cannot be conducted on a small amount of material without prior linear amplification of the RNA, which can interfere with the ability to differentiate small RNA family members and populations. The FirePlex® miRNA Discovery Panels are designed to overcome these limitations, and sensitively profile individual miRNAs using FirePlex® Particle technology.
This webinar will review:
Register today to hear more about this exciting topic and have your questions answered by Dr Arur during a live Q&A session!
Dr. Swathi Arur obtained her PhD with Prof. M.K. Bhan from the All India Institute of Medical Sciences. She undertook her post-graduate studies with Dr. David Han, at the UCONN Health Science Center, where she spearheaded one of the earliest efforts in deploying state-of-the-art differential proteomics technology (LC-MS/MS coupled with ICAT) to understand how dying cells were cleared by phagocytes. Her studies led to the discovery of the first ‘eat-me’ signal (Annexin I) secreted by the dying apoptotic cell, which enabled its recognition and removal by phagocytes.
Subsequently, Dr. Arur received a postdoctoral fellowship from the Washington University school of Medicine in St. Louis to train in the laboratory of Prof. Tim Schedl. During her postdoctoral training, Dr. Arur developed an approach that integrated bioinformatics, proteomics with the power of model-organism genetics to identify substrates of ERK – the terminal kinase of the RAS oncogenic pathway. Her studies discovered more than 30 new ERK targets and unraveled several new themes in RAS-ERK regulation.
Dr. Arur has run her research lab at the MD Anderson Cancer Center since 2010. She is a Research Scholar of the American Cancer Society, Anna Fuller Foundation, and Andrew Sabin Family Award. Her laboratory is currently funded by the National Institute of Health, Cancer Prevention and Research Institute of Texas and American Cancer Society.
Email the Abcam Events Team for the answers.
Interested in viewing additional webinars?
Learn about the latest research when and where you want to with Abcam's on-demand webinar library!